+147.7%
MRVL vs MRNA
+159.5%
-11.9%
-60.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.9% | +1.3% | -6.1% | -5.0% |
| 7D | -15.8% | -13.8% | -2.0% | -14.5% |
| 30D | -42.4% | -17.7% | -24.7% | -41.3% |
| 3M | -41.6% | +14.3% | -55.9% | -43.0% |
| 6M | -21.4% | +336.0% | -357.4% | -40.7% |
| YTD | +63.2% | +575.9% | -512.7% | +10.2% |
| 1Y | +70.6% | +724.4% | -653.8% | +9.4% |
| All | +147.7% | +159.5% | -11.9% | +90.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling